CJC-1295 & Ipamorelin Blend 5/5 mg

Buy CJC-1295 & Ipamorelin Blend from Adapt Peptides, a trusted peptides supplier in the US. This research-grade peptide combination is formulated to support studies on complementary growth hormone (GH) release pathways. Each vial is tested and verified by third-party labs to ensure purity levels exceeding 99%.

For your investigations in pulsatile GH secretion, cellular regeneration, and recovery processes, our CJC-1295 & Ipamorelin Blend for sale can be trusted for repeatable, reproducible outcomes. Order now for reliable, fast shipping in the United States. Note: For research purposes only. Not intended for human or veterinary use.

What Is CJC-1295 & Ipamorelin Blend?

The CJC-1295 & Ipamorelin blend is a laboratory-formulated research compound that combines two complementary peptides: CJC-1295, a growth hormone–releasing hormone (GHRH) analog, and Ipamorelin, a selective growth hormone secretagogue (GHS).

Together, these peptides are frequently studied in preclinical models for their potential to support pulsatile growth hormone release, muscle repair, and cellular recovery pathways.

CJC-1295

Adapt Peptides supplies CJC-1295 without DAC, a shorter-acting form designed to encourage GH release in a controlled, pulse-like fashion. Unlike DAC-modified versions, this formulation better reflects the body’s natural secretion cycles, helping to reduce the risk of receptor desensitization or growth hormone saturation.

Ipamorelin

Ipamorelin is a highly selective GHS that is often paired with GHRH analogs in research to amplify GH release while maintaining a favorable specificity profile. Its combination with CJC-1295 is of interest in studies exploring regenerative and metabolic functions.

Blend Properties

Adapt Peptides supplies the CJC-1295 + Ipamorelin in form of a lyophilized powder that dissolves readily in bacteriostatic water and maintains stability under standard peptide storage conditions.

This blend appears to have evolved within biohacking and aesthetic therapy communities through clinics combining the two well-studied peptides

While our CJC-1295 & Ipamorelin Blend focuses purely on growth hormone release and recovery, Glow Blend combines other peptides like GHK-Cu, BPC-157, and TB-500 for added skin regeneration, healing, and rejuvenation effects.

Note: Adapt Peptides sells the CJC-1295 + Ipamorelin blend for research purposes only. It is not approved for human use, medical treatment, or veterinary application.

Mechanism of Action: CJC-1295 & Ipamorelin (Research Basis)

The CJC-1295 & Ipamorelin blend promotes endogenous growth hormone (GH) release through two complementary mechanisms, acting on distinct receptor systems within the hypothalamic–pituitary axis.

CJC-1295 (GHRH Analog)

CJC-1295 is a synthetic peptide designed to mimic the actions of growth hormone–releasing hormone (GHRH). In research models, it binds directly to GHRH receptors located in the anterior pituitary, stimulating somatotroph cells to increase both the frequency and amplitude of growth hormone (GH) pulses[1]. This pulsatile pattern is important, as GH secretion in mammals naturally occurs in bursts rather than in a continuous stream.

Adapt Peptides offers CJC-1295 without DAC (Drug Affinity Complex). The absence of DAC significantly shortens its half-life, meaning the peptide is cleared more quickly from circulation compared to DAC-modified versions[2].

While DAC extensions are intended to prolong activity, they can also cause continuous GH exposure. Continuous exposure may increase the risk of receptor downregulation, desensitization, or disruption of the normal feedback loop governed by somatostatin and IGF-1.

By using the non-DAC form, researchers can study GH release patterns that more closely mirror natural physiology. This provides greater flexibility in experimental timing and dosage, while maintaining a research model that avoids the potential drawbacks of long-acting stimulation.

Ipamorelin (Ghrelin Mimetic)

Ipamorelin is a synthetic pentapeptide that acts as a highly selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), which is the same receptor activated by the endogenous hormone ghrelin. Activation of this receptor triggers the hypothalamic–pituitary axis, stimulating the release of growth hormone (GH) from the pituitary without directly altering growth hormone–releasing hormone (GHRH) pathways[3].

A defining characteristic of Ipamorelin is its selectivity. Earlier growth hormone secretagogues (such as GHRP-6 or hexarelin) were effective at stimulating GH release, but they also tended to activate other endocrine pathways, sometimes raising cortisol or prolactin levels. In contrast, Ipamorelin has been shown in animal and in vitro studies to exert minimal effects on these non-GH hormones, making it a more targeted tool for studying GH physiology[3].

By binding to ghrelin receptors, Ipamorelin not only promotes GH secretion but also supports a pulse-like release when paired with GHRH analogs such as CJC-1295. This makes it particularly useful in research models examining tissue regeneration, metabolic function, and the interplay between ghrelin signaling and age-related endocrine changes.

Synergistic Activity

When studied together, CJC-1295 and Ipamorelin act through different receptor targets—GHRH and ghrelin receptors—but converge on the shared outcome of increased GH release.

This dual stimulation often results in amplified and prolonged GH pulses, making the blend of interest in research examining muscle regeneration, tissue repair, lipid metabolism, and age-associated hormonal decline.

To date, these findings have been reported primarily in animal models and in vitro systems, and further research is ongoing to clarify their full potential.

CJC-1295 & Ipamorelin Blend Research Applications (Benefits)

In non-clinical and preclinical settings, the CJC-1295 & Ipamorelin combination has been widely studied for its influence on growth hormone (GH) signaling, with particular interest in its effects on muscle repair, metabolic activity, and cellular regeneration.

Because the peptides act through different receptor pathway, together they provide a dual model for examining GH-related physiology in vivo.

Muscle Recovery and Repair

Studies suggest that GH and its downstream mediator, insulin-like growth factor 1 (IGF-1), play a critical role in muscle hypertrophy, satellite cell activation, and tissue healing. By combining a GHRH analog and a ghrelin receptor agonist, the blend amplifies GH release, which in turn can elevate IGF-1 levels[4].

Research led by Teichman et al. (2006) demonstrated that CJC-1295 administration in healthy adults produced sustained increases in both GH and IGF-1 for several days after a single dose[5]. These prolonged elevations are of interest in experimental models focused on muscle regeneration, injury recovery, and age-related decline in anabolic signaling.

Growth Hormone Release Dynamics

Individually, CJC-1295 and Ipamorelin stimulate GH secretion via distinct pathways. CJC-1295 acts through pituitary GHRH receptors, while Ipamorelin activates the ghrelin receptor GHS-R1a.

When studied in tandem, they produce synergistic GH pulses that are stronger and more sustained than either compound alone. This makes the blend a useful research tool for exploring mechanisms of endocrine modulation and hormone feedback regulation.

Metabolic Pathway Exploration

Growth hormone influences energy metabolism through effects on liver, muscle, and adipose tissue. In animal studies[6]. As such, GH secretagogues have been associated with increased mitochondrial function, enhanced fatty acid oxidation, and improved regulation of glucose utilization.

For example, research in rodents has shown that GH-releasing peptides can modulate genes tied to lipid metabolism and oxidative pathways[7]. Such findings make the CJC-1295 & Ipamorelin blend relevant in investigations of metabolic flexibility and energy balance.

Fat Metabolism and Body Composition

Animal models have also been used to explore the relationship between GH pulses, adipose tissue reduction, and lean mass preservation. Elevated GH and IGF-1 have been linked to decreases in fat depots and improvements in glucose tolerance[8][9].

Importantly, Ipamorelin’s selective profile—showing minimal interaction with cortisol or prolactin—positions the blend as a targeted tool for studying body composition without some of the hormonal side effects observed in earlier GH secretagogues.

Other Observed Applications in Animal Studies

• Sleep and Circadian Rhythm: GH-releasing peptides have been reported to influence sleep cycles, particularly by extending slow-wave sleep phases[10].
• Tissue Regeneration: IGF-1–mediated pathways may contribute to repair of connective tissues, including tendons and cartilage[11].
• Neuroprotection: Some rodent studies suggest a potential role for GH signaling in neurogenesis and recovery following central nervous system injury[12].

CJC-1295 & Ipamorelin Blend — Peptide Characteristics

• Molecular Formula: CJC-1295 (no DAC variant): C₁₅₂H₂₅₂N₄₄O₄₂
  • Ipamorelin: C₃₈H₄₉N₉O₅
• CAS Number: CJC-1295: 863288-34-0, Ipamorelin: 170851-70-4
• PubChem CID: CJC-1295 (No DAC): 91976842, Ipamorelin: 9831659
• Amino Acid Sequence: CJC-1295 (no DAC variant): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-N-NH₂
  • Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH₂
• Synonyms: CJC-1295: CJC-1295 Without DAC, CJC-1295 Acetate
  • Ipamorelin: Ipamorelin, NNC 26-0161
• Molar Mass: CJC-1295 (No DAC): ≈ 3,367.9 g/mol
  • Ipamorelin: ≈ 711.868 g/mol
• Storage Recommendations: 
  • Lyophilized powder: Store refrigerated at 46 °F (≈ –8 °C) or colder, in a dry, light-protected environment for long-term stability
  • Reconstituted solution: Store at 36–46 °F (2–8 °C) and use within 30–45 days, or aliquot and freeze at 4 °F to –112 °F (–20 °C to –80 °C) to avoid freeze–thaw cycles

CJC-1295 + Ipamorelin vs Sermorelin + Ipamorelin vs Tesamorelin Comparison

CJC-1295 + Ipamorelin Safety and Side Effects in Studies

Across available preclinical investigations, both CJC-1295 and Ipamorelin have shown a favorable safety profile when evaluated at research-appropriate doses. In animal models, these peptides have been observed to enhance growth hormone (GH) secretion without triggering major off-target hormonal effects[5].

The non-DAC version of CJC-1295 (Modified GRF 1-29) is shorter-acting, which allows for GH release patterns that align more closely with natural pulsatility. This helps avoid the risk of prolonged receptor activation. Ipamorelin adds to this profile by selectively activating the ghrelin receptor, producing GH release while exerting minimal influence on cortisol or prolactin levels — an improvement compared to earlier GH secretagogues such as GHRP-6 [1][2].

That said, the evidence base remains limited. Long-term human safety data are not available, and much of what is known comes from small-scale or animal research. Adapt Peptides does not in any way endorse the safety or tolerability of our peptides for sale, which are research-only.

Occasional anecdotal reports mention transient water retention or mild irritation at the site of administration, though these effects have not been confirmed in larger, controlled studies.

Legal Disclaimer

Adapt Peptides distributes CJC-1295 & Ipamorelin blend exclusively for laboratory research use. It is not intended for human or veterinary consumption and should not be used for therapeutic, diagnostic, or resale purposes.

By purchasing and using this compound, you agree to take full responsibility for its safe use and adhere to all local, state, and federal laws and regulations.

Certificate of Analysis (COA)

All CJC-1295 & Ipamorelin Blend batches provided by Evolve Peptides are analyzed by accredited third-party laboratories to ensure compliance with rigorous quality standards. Each COA verifies:

• Molecular identity
• Purity and peptide composition
• Absence of detectable contaminants

Typical results exceed 99% purity, underscoring batch-to-batch consistency and reliability. COAs are made available with every order, and researchers may request digital or printed copies for their records.

Scientific References

1. Madalina Ionescu, Lawrence A. Frohman, Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog, The Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 12, 1 December 2006, Pages 4792–4797. 

https://academic.oup.com/jcem/article-abstract/91/12/4792/2656274 

2. ConjuChem, LLC. (n.d.). About DAC™: Drug Affinity Complex technology. ConjuChem. https://www.conjuchem.com/technology/dac.html
3. K Raun, B S Hansen, N L Johansen, H Thogersen, K Madsen, M Ankersen, P H Andersen, Ipamorelin, the first selective growth hormone secretagogue, European Journal of Endocrinology, Volume 139, Issue 5, Nov 1998, Pages 552–561.

https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390 

4. Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020 Aug 26;9(9):1970.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7564605/ 

5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805.

https://pubmed.ncbi.nlm.nih.gov/16352683/ 

6. Tavares, M. R., Frazao, R., & Donato, J. Jr. (2023). Understanding the role of growth hormone in situations of metabolic stress. Journal of Endocrinology, 256(1)

https://joe.bioscientifica.com/view/journals/joe/256/1/JOE-22-0159.xml 

7. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010 Feb;20(1):1-7.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2815161/ 

8. Lewitt MS. The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity. Biochem Insights. 2017 Apr 20;10:1178626417703995.

https://pmc.ncbi.nlm.nih.gov/articles/PMC5404904/ 

9. Berryman DE, List EO. Growth Hormone’s Effect on Adipose Tissue: Quality versus Quantity. Int J Mol Sci. 2017 Jul 26;18(8):1621.

https://pmc.ncbi.nlm.nih.gov/articles/PMC5578013/ 

10. Peterfi Z, McGinty D, Sarai E, Szymusiak R. Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2010 Jan;298(1):R147-56.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2806209/ 

11. Chen Y, Zhu Y, Song S, Hu Y. Contribution of insulin‑like growth factor‑1 to tendon repair (Review). Int J Mol Med. 2025 Nov;56(5):195.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12440272/ 

12. Larissa Joy Christophidis, Thorsten Gorba, Malin Gustavsson, Chris Edward Williams, George Arthur Werther, Vincenzo Carlo Russo, Arjan Scheepens. Growth hormone receptor immunoreactivity is increased in the subventricular zone of juvenile rat brain after focal ischemia: A potential role for growth hormone in injury-induced neurogenesis,

Growth Hormone & IGF Research, Volume 19, Issue 6, 2009, Pages 497-506.

https://www.sciencedirect.com/science/article/abs/pii/S109663740900080X